Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti...
Brief Summary
Official Title: “Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent”
Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen
- Study Type: Observational
- Study Design: Observational Model: Case-Only, Time Perspective: Retrospective
- Study Primary Completion Date: March 2010
Outcome Measures for this Clinical Trial
Primary Measures
- To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.
Secondary Measures
- To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- pathologic confirmation of prostate cancer
- patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.
Exclusion Criteria:
- patients who are hard to be analysed by limitation of chart record according to investigators'discretion
- patients who already have been registered in this study
Gender Eligibility for this Clinical Trial: Male
Minimum Age for this Clinical Trial: N/A
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: AstraZeneca Industry
Overall Clinical Trial Officials and Contacts
Joon Woo Bahn, MD Study Director AstraZeneca Korea
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01025479
Study ID Number: NIS-OKR-CAS-2009/1
ClinicalTrials.gov Identifier: NCT01025479
Health Authority: Korea: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01025479
